- Next Steps: Get Started Prescribing Buprenorphine!
- How to Assess and Treat Patients with Comorbid Health Issues
- How to Conduct Buprenorphine Induction
- How to Establish and Manage a Buprenorphine Practice
- How to Manage Challenging Patients
- How to Comply with Rules, Regulations, and Recordkeeping
- How to Understand Insurance and Billing Issues
- Commonly Used CPT Codes - Primary Care
- Commonly Used CPT Codes for Counseling - Primary Care
- Commonly Used CPT Codes for Buprenorphine Treatment - Psychiatrists
- Overview of Medicaid Coverage
- Setting Up a Cash-Only Buprenorphine Treatment Program
- Overview of Medicare Coverage
- Overview of Private Insurance Coverage
- Cost of Buprenorphine Treatment to Patients
- How to Screen for Substance Abuse
- How to Refer Patients to an Addiction Specialist
- Review: What is Buprenorphine?
Cost of Buprenorphine Treatment to Patients
The cost of buprenorphine can vary depending on the dose. Cost of a dose of buprenorphine is determined by:
- The pharmaceutical company, Reckitt Benckiser for Suboxone and other companies that produce generic buprenorphine
- The health plan
- Retail pharmacies
Daily doses are normally from 8 mg to 24 mg, and the average retail price for these doses ranges from $4-$19 per day (Sullivan and Fiellin, 2008).
Patients who do not have health insurance can expect to pay around $500 per month for buprenorphine treatment, which includes the cost of the medication plus the cost of doctor's visits. These estimates are based on an average dose of 16mg/day ($12 x 30 days = $360) plus $100-$200 fee for office-visits. Of course, these rates will vary based on factors such as geographic location and proximity of other providers.
A variety of prescription discounts are available for low-income patients.
- Reckitt Benckiser's Suboxone Prescription Assistance Program
- Free Drug Card Program
- AAA members can save an average of 20% off the retail price of prescriptions, valid at participating pharmacies.
Update: As of March 2013, two companies, Amneal Pharmaceuticals and Actavis, were approved by the FDA to market a generic combination buprenorphine/naloxone tablet. This may significantly reduce the cost to patients.
Sullivan, L, Fiellin, D. Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice. Annals of Internal Medicine. 2008; 148(9): 662-670.
This pie chart shows the breakdown of how buprenorphine patients paid for their doctor's visits. 204 patients in NAABT's physician-patient matching system were surveyed.
The National Alliance of Advocates for Buprenorphine Treatment (NAABT)
This study examines decision-making in the buprenorphine treatment distribution and payment systems. The study is based on interviews with health care leaders involved in the distribution and adoption of buprenorphine.
The Center for Substance Abuse Treatment (CSAT)